PeterGreenbergMD

PubMed

• 18 citations
  Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations
  Simone Feurstein, Ayodeji Adegunsoye, Danijela Mojsilovic, Rekha Vij, Allison H. West DePersia, Padma Sheila Rajagopal, Afaf Osman, Robert H. Collins, Raymond H. Kim, ...> ;Blood Advances. 2020 Oct 13
• 23 citations
  Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes
  Emanuele Angelucci, Peter L. Greenberg, Miguel Izquierdo, Guillermo Garcia-Manero> ;Annals of Internal Medicine. 2020 Oct 6
• 307 citations
  Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
  Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian, Sean M. Devlin, Heinz Tuechler, Juan S. Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Lu...> ;Nature Medicine. 2020 Aug 3
• 164 citations
  SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
  Luca Malcovati, Kristen E. Stevenson, Elli Papaemmanuil, Donna Neuberg, Rafael Bejar, Jacqueline Boultwood, David T. Bowen, Peter J. Campbell, Benjamin L. Ebert, Pierr...> ;Blood. 2020 Jul 9
• 45 citations
  Myelodysplastic syndromes: moving towards personalized management
  Eva Hellström-Lindberg, Magnus Tobiasson, Peter L. Greenberg> ;Haematologica. 2020 Jul 1
• 42 citations
  Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS
  Andrea Kuendgen, M. Nomdedeu, Heinz Tuechler, G. Garcia-Manero, Rami S. Komrokji, Mikkael A. Sekeres, M.G. Della Porta, Mario Cazzola, Amy E. DeZern, Gail J. Roboz, Da...> ;Leukemia. 2021 Mar 1
• 18 citations
  Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms.
  Michael A. Spinner, Alexey Aleshin, Marianne Santaguida, Steven Schaffert, James L. Zehnder, A Scott Patterson, Christos Gekas, Diane Heiser, Peter L. Greenberg> ;Blood Advances. 2020 Jun 23
• 18 citations
  Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
  Asiri Ediriwickrema, Ritika Dutta, Shyam A. Patel, William Shomali, Bruno C. Medeiros, David J. Iberri, Jason Gotlib, Gabriel N. Mannis, Peter L. Greenberg, Ravindra M...> ;Leukemia & Lymphoma. 2020 Jun 16
• 41 citations
  Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
  Emanuele Angelucci, Junmin Li, Peter L. Greenberg, Depei Wu, Ming Hou, Efreen Montaño Figueroa, Maria Guadalupe Rodriguez, Xunwei Dong, Jagannath Ghosh, Miguel Izquier...> ;Annals of Internal Medicine. 2020 Apr 21
• 31 citations
  Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage with Evidence Development Study
  Ehab Atallah, Brent R. Logan, Min Chen, Corey Cutler, J. Deeg, Meagan A. Jacoby, Richard E. Champlin, Taiga Nishihori, Dennis L. Confer, James Gajewski, Stephanie Farn...> ;JAMA Oncology. 2020 Apr 1
• 4 citations
  Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large w...
  Alexander B Pine, Nora Chokr, Maximilian Stahl, David P. Steensma, Mikkael A. Sekeres, Mark R. Litzow, Selina M. Luger, Richard Stone, Peter L. Greenberg, Rafael Bejar...> ;Leukemia & Lymphoma. 2020 Feb 6
• 19 citations
  Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation.
  Gregory K. Behbehani, Rachel Finck, Nikolay Samusik, Kunju Sridhar, Wendy J. Fantl, Peter L. Greenberg, Garry P. Nolan> ;Cytometry. Part B, Clinical Cytometry. 2020 Jan 9
• 274 citations
  Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
  Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, Guillermo Garcia-Manero, Rena Buckstein, Valeria Santini, María Díez-Campelo, Carlo Finelli, Mario Cazzola, Osman Ilha...> ;The New England Journal of Medicine. 2020 Jan 8
• 79 citations
  Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
  Peter Valent, Attilio Orazi, Michael R. Savona, Mrinal M. Patnaik, Francesco Onida, Arjan A. van de Loosdrecht, Detlef Haase, Torsten Haferlach, Chiara Elena, Lisa Ple...> ;Haematologica. 2019 Oct 1
• 13 citations
  MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-β pathways.
  Minyoung Youn, Haigen Huang, Cheng Chen, Sharon Kam, Mark C. Wilkes, Hee-Don Chae, Kunju Sridhar, Peter L. Greenberg, Bertil Glader, Anupama Narla, Shuo Lin, Kathleen ...> ;Blood Advances. 2019 Sep 24
• 148 citations
  TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
  Detlef Haase, Kristen E. Stevenson, Donna Neuberg, Jaroslaw P. Maciejewski, Aziz Nazha, Mikkael A. Sekeres, Benjamin L. Ebert, Guillermo Garcia-Manero, Claudia Haferla...> ;Leukemia. 2019 Jan 11
• 4 citations
  Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results f...
  Ronan T. Swords, Peter L. Greenberg, Andrew H. Wei, Simon Durrant, Anjali S. Advani, Mark Hertzberg, Ian D. Lewis, Gabriel Rivera, Dita Gratzinger, Alice C. Fan, Dean ...> ;Leukemia Research. 2017 Aug 1
• 126 citations
  Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
  Peter Valent, Attilio Orazi, David P. Steensma, Benjamin L. Ebert, Detlef Haase, Luca Malcovati, Arjan A. van de Loosdrecht, Torsten Haferlach, Theresia M. Westers, De...> ;Oncotarget. 2017 Jul 5
• 220 citations
  Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology
  Peter L. Greenberg, Richard Stone, Aref Al-Kali, Stefan K. Barta, Rafael Bejar, John M. Bennett, Hetty E. Carraway, Carlos M. de Castro, H. Joachim Deeg, Amy E. DeZern...> ;Journal of the National Comprehensive Cancer Network. 2017 Jan 1
• 5 citations
  The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders
  Rafael Bejar, Peter Greenberg> ;Journal of the National Comprehensive Cancer Network. 2017 Jan 1
• 41 citations
  KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study
  Ronan T. Swords, Peter L. Greenberg, Andrew H. Wei, Simon Durrant, Anjali S. Advani, Mark Hertzberg, Ian D. Lewis, Gabriel Rivera, Dita Gratzinger, Alice C. Fan, Dean ...> ;Leukemia Research. 2016 Nov 1
• 118 citations
  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
  Ayalew Tefferi, Hagop M. Kantarjian, S. Vincent Rajkumar, Larry Baker, J L Abkowitz, John W. Adamson, Ranjana H. Advani, James P. Allison, Karen H. Antman, Robert C. B...> ;Mayo Clinic Proceedings. 2015 Aug 1
• 4 citations
  Synergistic Interactions of Molecular and Clinical Advances for Characterizing the Myelodysplastic Syndromes
  Peter L. Greenberg> ;Journal of the National Comprehensive Cancer Network. 2015 Jul 1
• 1 citations
  Update on Myelodysplastic Syndromes Classification and Prognosis.
  Dita Gratzinger, Peter L. Greenberg> ;Surgical Pathology Clinics. 2013 Dec 1
• 18 citations
  Reduced rRNA expression and increased rDNA promoter methylation in CD34 + cells of patients with myelodysplastic syndromes
  Aparna Raval, Kunju Sridhar, Shripa Patel, Brit B. Turnbull, Peter L. Greenberg, Beverly S. Mitchell> ;Blood. 2012 Dec 6
• Join now to see all